Diabetes, Vol 44, Issue 10 1218-1226, Copyright © 1995 by American Diabetes Association

ARTICLES

Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial

JQ Purnell, SM Marcovina, JE Hokanson, H Kennedy, PA Cleary, MW Steffes and JD Brunzell
Division of Metabolism, Endocrinology, School of Public Health and Community Medicine, University of Washington, Seattle 98195, USA.

Levels of lipoprotein(a) [Lp(a)], apolipoprotein (apo) B, and lipoprotein cholesterol distribution using density-gradient ultracentrifugation were measured as part of a cross-sectional study at the final follow-up examination (mean 6.2 years) in the Diabetes Control and Complications Trial. Compared with the subjects in the conventionally treated group (n = 680), those subjects receiving intensive diabetes therapy (n = 667) had a lower level of Lp(a) (Caucasian subjects only, median 10.7 vs 12.5 mg/dl, respectively; P = 0.03), lower apo B (mean 83 vs. 86 mg/dl, respectively; P = 0.01), and a more favorable distribution of cholesterol in the lipoprotein fractions as measured by density-gradient ultracentrifugation with less cholesterol in the very-low-density lipoprotein and the dense low-density lipoprotein fractions and greater cholesterol content of the more buoyant low-density lipoprotein. Compared with a nondiabetic Caucasian control group (n = 2,158), Lp(a) levels were not different in the intensive treatment group (median 9.6 vs. 10.7 mg/dl, respectively; NS) and higher in the conventional treatment group (9.6 vs. 12.5 mg/dl, respectively; P < 0.01). No effect of renal dysfunction as measured by increasing albuminuria or reduced creatinine clearance on Lp(a) levels could be demonstrated in the diabetic subjects. Prospective follow-up of these subjects will determine whether these favorable lipoprotein differences in the intensive treatment group persist and whether they influence the onset of atherosclerosis in insulin-dependent diabetes.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Q. Purnell, R. K. Dev, M. W. Steffes, P. A. Cleary, J. P. Palmer, I. B. Hirsch, J. E. Hokanson, and J. D. Brunzell Relationship of Family History of Type 2 Diabetes, Hypoglycemia, and Autoantibodies to Weight Gain and Lipids With Intensive and Conventional Therapy in the Diabetes Control and Complications Trial Diabetes, October 1, 2003; 52(10): 2623 - 2629. [Abstract] [Full Text] [PDF]

				R. H. Knopp, B. Retzlaff, B. Fish, C. Walden, S. Wallick, M. Anderson, K. Aikawa, and S. E. Kahn Effects of Insulin Resistance and Obesity on Lipoproteins and Sensitivity to Egg Feeding Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1437 - 1443. [Abstract] [Full Text] [PDF]

				K. L. Herbst, J. K. Amory, J. D. Brunzell, H. A. Chansky, and W. J. Bremner Testosterone administration to men increases hepatic lipase activity and decreases HDL and LDL size in 3 wk Am J Physiol Endocrinol Metab, June 1, 2003; 284(6): E1112 - E1118. [Abstract] [Full Text] [PDF]

				A. J. Jenkins, T. J. Lyons, D. Zheng, J. D. Otvos, D. T. Lackland, D. McGee, W. T. Garvey, R. L. Klein, and The DCCT/EDIC Research Group Serum Lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Cohort: Associations with gender and glycemia Diabetes Care, March 1, 2003; 26(3): 810 - 818. [Abstract] [Full Text] [PDF]

				D. J. Nieves, M. Cnop, B. Retzlaff, C. E. Walden, J. D. Brunzell, R. H. Knopp, and S. E. Kahn The Atherogenic Lipoprotein Profile Associated With Obesity and Insulin Resistance Is Largely Attributable to Intra-Abdominal Fat Diabetes, January 1, 2003; 52(1): 172 - 179. [Abstract] [Full Text] [PDF]

				M. C. Carr, J. E. Hokanson, A. Zambon, S. S. Deeb, P. H. R. Barrett, J. Q. Purnell, and J. D. Brunzell The Contribution of Intraabdominal Fat to Gender Differences in Hepatic Lipase Activity and Low/High Density Lipoprotein Heterogeneity J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2831 - 2837. [Abstract] [Full Text] [PDF]

				M. C. Carr, J. E. Hokanson, S. S. Deeb, J. Q. Purnell, E. S. Mitchell, and J. D. Brunzell A Hepatic Lipase Gene Promoter Polymorphism Attenuates the Increase in Hepatic Lipase Activity With Increasing Intra-abdominal Fat in Women Arterioscler. Thromb. Vasc. Biol., November 1, 1999; 19(11): 2701 - 2707. [Abstract] [Full Text] [PDF]

				J. Q. Purnell, J. E. Hokanson, S. M. Marcovina, M. W. Steffes, P. A. Cleary, and J. D. Brunzell Effect of Excessive Weight Gain With Intensive Therapy of Type 1 Diabetes on Lipid Levels and Blood Pressure: Results From the DCCT JAMA, July 8, 1998; 280(2): 140 - 146. [Abstract] [Full Text] [PDF]